NCT05168644View on ClinicalTrials.gov

Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 14, 2021

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions
Healthy
Interventions
DRUG

Niclosamide Inhalation Powder

Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.

DRUG

Placebo

Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.

Trial Locations (1)

Unknown

Altasciences, Mount Royal

All Listed Sponsors
lead

TFF Pharmaceuticals, Inc.

INDUSTRY

NCT05168644 - Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter